Neurotherapeutic composition and method therefor

a neuropsychiatric and composition technology, applied in the direction of peptide/protein ingredients, peptide sources, metabolic disorders, etc., to achieve the effects of improving learning and memory, reducing impulsivity and violence, and reducing disorientation

Inactive Publication Date: 2007-10-25
REVAAX PHARMA LLC
View PDF3 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0007] Exemplary of cognitive and behavioral disorders susceptible to treatment in accordance with this invention include aggressive disorder, obsessive compulsive disorder, anxiety, depression, ADHD, and memory impairment. Animal data suggest that the method and formulation of this invention have potential as an antiaggressive agent to control impulsivity and violence in autism, T

Problems solved by technology

Such disorders typically derive fro

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Neurotherapeutic composition and method therefor
  • Neurotherapeutic composition and method therefor
  • Neurotherapeutic composition and method therefor

Examples

Experimental program
Comparison scheme
Effect test

experimental examples

[0055] Marketed in 1981-1982 moxalactam (Mox) was employed widely in the world as a third-generation cephalosporin-like antibiotic. Clinical efficacy and safety were evaluated in over 2200 patents with bacterial infections (Jackson et al. 1986). Of the 260 patents treated with Mox for gram-negative meningitis, 241 (93%) showed satisfactory response to antibiotic therapy. Patents were treated with 4 g of Mox every 8 hrs for 2-3 weeks. Peak plasma concentrations occur within an one hr after IM injection with an elimination half-life of 2.3 hrs. There is no accumulation with multiple injections occurring at 8-12 hr intervals. Moxalactam can penetrate the blood brain barrier. Cerebrospinal fluid (CSF) levels of Mox range from 25-39 μg / ml following a 2.0 g IV dose of drug. The CSF concentration as a percentage of serum concentration is estimated to be 20%. The D isomer has antibacterial activity and has a greater unbound fraction to plasma protein that the L isomer.

Behavioral Studies wi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Neurotherapeutically effective pharmaceutical compositions are described that include carboxypeptidase E inhibitors. One class of carboxypeptidase E inhibitors found to exhibit significant neurotropic activity are β-lactam compounds, particularly penam and cephem β-lactam antibiotics and non-antibiotic derivatives thereof.

Description

[0001] This application is a continuation of U.S. patent application Ser. No. 09 / 783,201, filed Feb. 14, 2001, which is expressly incorporated by reference herein.FIELD OF INVENTION [0002] This invention relates to a novel mechanism of neuropsychiatric intervention. More particularly, this invention is directed to pharmaceutical formulations and methods for treatment of a variety of neurological disease states, including cognitive and behavioral disorders. BACKGROUND AND SUMMARY OF THE INVENTION [0003] The pharmaceutical industry has directed extensive research and development efforts toward discovery and commercialization of drugs for treatment of neurological disorders. Such disorders typically derive from chemical imbalances in the brain. Overproduction or underproduction of pertinent neurochemical species and / or receptor dysfunction has been identified with many disease states recognized by neurologists, psychiatrists, psychologists and other medical practitioners skilled in the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/16A61K31/00A61K31/197A61K31/198A61K31/395A61K31/424A61K31/43A61K31/431A61K31/4353A61K31/5365A61K31/5383A61K31/545A61K31/546A61K45/06
CPCA61K31/00A61K31/197A61K45/06A61K38/08A61K31/198A61K31/395A61K31/424A61K31/43A61K31/431A61K31/4353A61K31/536A61K31/5365A61K31/5383A61K31/545A61K31/546A61K2300/00A61P25/00A61P25/22
Inventor KOPPEL, GARY A.CHANEY, MICHAEL O.
Owner REVAAX PHARMA LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap